Moderna in the News
New York Times, March 21, 2013: AstraZeneca to Pay $240 Million to Moderna Therapeutics
Xconomy, March 21, 2013: AstraZeneca Shells Out $240 Upfront For Moderna mRNA Drugs
Boston Magazine, February 26, 2013: Does Moderna Therapeutics Have the Next Big Thing in Biotech?
Xconomy, December 6, 2012: Moderna, $40M in Tow, Hopes to Reinvent Biotech with “Make Your Own Drug”.
April 30, 2013: Moderna welcomes Henri A. Termeer, former CEO of Genzyme, to its board of directors
March 21, 2013: AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer
February 27, 2013: Massachusetts Life Sciences Center awards tax incentives to 25 companies
January 16, 2013: Moderna appoints Divakar Ramamakishnan, Ph.D., as Senior Vice President of Process Development, Manufacturing and Quality.
December 19, 2012: Moderna has appointed Stephen Hoge, formerly of McKinsey & Company, as Senior Vice President of Corporate Development and New Drug Concepts.
December 6, 2012: Moderna Announces $40 Million in Financing to Advance Development of New Biotherapeutic Modality: Messenger RNA Therapeutics™
February 22, 2012: Massachusetts Life Sciences Center Announces Tax Incentives Targeting Growth at 28 Companies
Center Awards $21.2 million to foster job growth in the Massachusetts Life Sciences sectors
December 9, 2010: Flagship VentureLabs Company ModeRNA Therapeutics, and co-founder, Derrick Rossi, both Cited by Time Magazine for Significant Advances and Contributions in 2010
September 30, 2010: Flagship VentureLabs company, ModeRNA Therapeutics, Announces Safe and Efficient Method for Creating and Differentiating Human Pluripotent Stem Cells